ClinicalTrials.gg
RecruitingNCT07093359GOLFUpdated Aug 5, 2025

LINX vs Fundoplication

A Phase 3 interventional study of Laparoscopic or robotic LINX procedure and Laparoscopic or robotic fundoplication in Gastro-oesophageal Reflux Disease, sponsored by University of Oxford. Recruiting at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by University of Oxford · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Gastroesophageal Reflux with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Gastroesophageal Reflux · United Kingdom.

Planned enrollment
6th of 32
460 · median 64
Started
2025
with 2 others
Phase 3
5 of 53
1 open now
Registered
51st of 53
by date

Among the 53 studies in Gastroesophageal Reflux with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 3, and was the 51st registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 53 studies in Gastroesophageal Reflux with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Gastroesophageal Reflux with a site in United Kingdom, or all of them as a file.
02

Study summary

Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.

03

Conditions studied

  • Gastro-oesophageal Reflux Disease

Keywords

  • LINX
  • GORD
  • GERD
  • Fundoplication
  • REFLUX
  • ANTI REFLUX
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years and above
  2. Willing and able to give
  3. Patients with GORD insufficiently controlled by medical therapy or intolerance to medical therapy being considered for anti-reflux surgery
  4. Symptomatic and objectively defined GORD; endoscopy with appearances or consistent with reflux oesophagitis, or 24-hour pH study or BRAVO test of the oesophagus consistent with GORD
  5. No hiatal hernia or hiatal hernia \<5 cm in length
  6. Adequate lower oesophageal motility as defined by preoperative oesophageal manometry study. Oesophageal manometry will show a mean contractile amplitude of >30 mmHg or DCI >450 mmHg-s-cm in 70% of swallows.

Exclusion criteria

Exclusion Criteria:

  1. Unsuitable for surgical intervention due to medical conditions precluding general anaesthesia
  2. Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials
  3. Previous anti-reflux or gastric surgery
  4. Previous or planned neurosurgical intervention
  5. Oesophageal manometry showing complete absence of lower oesophageal contractility
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
460 participants (estimated)

Study arms

  • Active comparator
    Laparoscopic or robotic fundoplication

    Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.

    Procedure: Laparoscopic or robotic fundoplication

  • Experimental
    Laparoscopic or robotic LINX procedure

    Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.

    Procedure: Laparoscopic or robotic LINX procedure

Interventions

  • ProcedureLaparoscopic or robotic LINX procedure

    Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.

  • ProcedureLaparoscopic or robotic fundoplication

    Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.

06

What researchers measure

Primary outcomes

  1. Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire

    Time frame: 24 months following surgery

Secondary outcomes

  1. Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 24 months postoperatively

  2. Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 24 months postoperatively

  3. Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 6 weeks, 6 and 12 months after surgery

  4. Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  5. Global HRQL measured using participant-reported outcomes/EQ-5D-5L questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  6. Utilisation of anti-GORD medications measured using participant-reported outcomes/questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  7. 24-hour pH measurement measured using participant's medical records/24-hour pH measurement or BRAVO test

    Time frame: 12 months postoperatively

  8. Postoperative complication rates, including reoperation and endoscopic reintervention, measured using participant's medical records/postoperative outcomes

    Time frame: 30-day, 90-day, 12 and 24-month

  9. Cost-effectiveness of both treatments as measured by incremental cost per quality-adjusted life year (QALY)

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

07

Study locations

5 of 5 sites recruiting
  • Guy's and St Thomas's NHS Foundation Trust, Guy's and St Thomas's Hospital
    Oxford, Oxfordshire OX3 7LD, United Kingdom
    Recruiting
  • Imperial College Healthcare NHS Trust, St Mary's Hospital
    Oxford, Oxfordshire OX3 7LD, United Kingdom
    Recruiting
  • Leeds Teaching Hospitals NHS Trust, St James's University Hospital
    Oxford, Oxfordshire OX3 7LD, United Kingdom
    Recruiting
  • Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
    Oxford, Oxfordshire OX3 7LD, United Kingdom
    Recruiting
  • University Hospital Southampton NHS Foundation Trust
    Oxford, Oxfordshire OX3 7LD, United Kingdom
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — The data-sharing plans for the current study are unknown and will be made available at a later date.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2029, 47 months after the start.

Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 30, 2025
StartActual
Mar 6, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Jul 2029
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093359
Collaborators
King's College London, Imperial College London, Oxford University Hospitals NHS Trust, Guy's and St Thomas' NHS Foundation Trust, University of Bristol, University of Southampton
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Mar 6, 2025
Primary completion
Feb 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Aug 5, 2025

Study contacts

Sheraz Markar, PhD, FRCS, MSc, MA
Contact
golf@nds.ox.ac.uk
+44 07584039433

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion